VC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
VC is not a good buy right now for an impatient investor. The stock is in a clear short-term downtrend (bearish moving-average stack, price below key pivot), and there are no Intellectia buy-type signals to override that. With bearish short-term pattern probabilities and cautious Street stance (Equal Weight + recent target cut), the near-term risk/reward looks unfavorable.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. MACD histogram (-0.381) is below zero but contracting, implying downside momentum is weakening (possible stabilization), not yet a reversal. RSI(6)=36.8 is weak and near oversold territory, which can produce bounces, but it is not a confirmed buy signal. Price (89.32) is below S1 (90.231) and close to S2 (88.364); near-term support is 88.36–90.23, while upside resistance/pivot sits around 93.25 then 96.27. Pattern-based stats are bearish: estimated odds point to ~-4.31% next week and ~-7.28% next month.
Intellectia Proprietary Trading Signals
on 2026-02-17 pre-market could be a catalyst if margins/EPS remain strong.
indicates more hedging/defensive positioning. Analyst actions are cautious with a notable recent target cut (Barclays 130 ->
and multiple Equal Weight ratings. News items provided appear unrelated to Visteon (mentions Tutor Perini), so there is no clear supportive company-specific news catalyst in the feed.
Latest reported quarter: 2025/Q3. Revenue declined to $917M (-6.43% YoY), but profitability improved meaningfully: net income $57M (+46.15% YoY), EPS $2.04 (+45.71% YoY), and gross margin 14.29% (up 6.88% YoY). This is a quality-of-earnings positive (margin expansion), but the top-line contraction limits upside enthusiasm until revenue growth re-accelerates.
Recent Wall Street trend: cautious/neutral. Morgan Stanley initiated/assumed coverage at Equal Weight with $114 target (2025-12-08). Barclays kept Equal Weight but cut target to $110 from $130 (2026-01-23), signaling reduced upside expectations. Pros: targets ($110–$114) still sit above the current price (~$89), implying theoretical upside if execution holds. Cons: both are not Buy ratings, and the recent target cut reinforces a more conservative outlook into 2026.
